Inflammation & Longevity Biomarker Panel

Advanced inflammatory biomarker panel measuring CRP, IL-6, TNF-alpha, homocysteine, and oxidative stress markers to quantify chronic low-grade inflammation — the primary driver of biological ageing and age-related disease.

Chronic low-grade inflammation — increasingly termed 'inflammageing' in longevity science — is now recognised as the central mechanism driving biological ageing and the development of virtually every major age-related condition, including cardiovascular disease, neurodegeneration, type 2 diabetes, and cancer. Unlike acute inflammation, inflammageing operates below the threshold of symptoms, silently accelerating cellular damage over decades. At Lifespan Asia, the inflammation and longevity biomarker panel goes beyond standard CRP to measure a clinically meaningful spectrum of inflammatory and metabolic markers. High-sensitivity CRP (hsCRP) provides cardiovascular and systemic inflammation context; interleukin-6 (IL-6) reflects the pro-inflammatory cytokine environment central to muscle wasting, insulin resistance, and cognitive decline; TNF-alpha quantifies macrophage-driven inflammation relevant to metabolic syndrome and cardiovascular risk. Homocysteine — an amino acid that accumulates when B-vitamin methylation pathways are compromised — is included because elevated levels independently predict cardiovascular events, dementia, and bone fragility at concentrations often dismissed as 'borderline normal' on standard panels. Oxidative stress markers including 8-OHdG (a DNA damage marker) and F2-isoprostanes provide direct evidence of free-radical burden at the cellular level. For longevity medicine clients, understanding the baseline inflammation landscape is essential before initiating any therapeutic protocol. HBOT has demonstrated measurable anti-inflammatory effects in peer-reviewed research; NAD+ infusions downregulate NF-kB inflammatory signalling; targeted supplementation based on micronutrient panel results addresses root nutritional drivers. The inflammation panel enables Lifespan Asia physicians to prioritise interventions, set reduction targets, and document objective improvement as protocols take effect. Re-testing at three to six month intervals tracks inflammageing trajectory and validates the clinical response to the longevity programme.